ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Withdrawn

Conditions: Stage IIA Fallopian Tube Cancer
Stage IIIB Ovarian Cancer
Stage IIIC Ovarian Cancer
Stage IIIA Fallopian Tube Cancer
Stage IIIA Primary Peritoneal Cancer
Stage IV Fallopian Tube Cancer
Recurrent Fallopian Tube Carcinoma
Stage IIIB Fallopian Tube Cancer
Stage IIIC Primary Peritoneal Cancer
Stage IV Primary Peritoneal Cancer

Interventions: Other: Laboratory Biomarker Analysis
Biological: Recombinant NY-ESO-1 Protein
Drug: Sirolimus

First Posted Date: 2016-07-14

Last Posted Date: 2018-05-01

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT02833506

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Recurrent Colorectal Carcinoma
Stage IVB Colorectal Cancer
Stage IVA Colorectal Cancer

Interventions: Biological: Cetuximab
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2016-03-18

Last Posted Date: 2022-10-06

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 45

Registration Number: NCT02713373

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Phase 1

Active, not recruiting

Conditions: Metastatic Fallopian Tube Carcinoma
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Stage III Fallopian Tube Cancer AJCC v8
Stage IIIA Ovarian Cancer AJCC v8
Stage IIIB Primary Peritoneal Cancer AJCC v8
Stage IIIC Ovarian Cancer AJCC v8
Unresectable Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Metastatic Melanoma
Metastatic Ovarian Carcinoma

Interventions: Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Drug: Decitabine
Procedure: Leukapheresis
Biological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes

First Posted Date: 2016-01-08

Last Posted Date: 2024-06-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT02650986

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Nicotine Delivery From Novel Non-Tobacco Electronic System in Smokers

Not Applicable

Completed

Conditions: Healthy Subject
Cigarette Smoker
Current Smoker

Interventions: Other: Electronic Cigarette
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Questionnaire Administration

First Posted Date: 2015-10-15

Last Posted Date: 2018-06-12

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 36

Registration Number: NCT02575885

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer

Phase 1

Withdrawn

Conditions: Colon Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Rectal Adenocarcinoma
Stage III Pancreatic Cancer
Stage IVA Rectal Cancer
Stage IIIA Colon Cancer
Stage IIIB Colon Cancer
Stage IIIC Colon Cancer

Interventions: Drug: Fluorouracil
Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Oxaliplatin
Drug: pan FGFR Kinase Inhibitor BGJ398
Other: Pharmacological Study

First Posted Date: 2015-10-14

Last Posted Date: 2016-05-20

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT02575508

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation

Phase 1

Completed

Conditions: Stomatitis
Head and Neck Squamous Cell Carcinoma
Pain

Interventions: Drug: Gabapentin
Other: Quality-of-Life Assessment
Drug: Methadone Hydrochloride
Other: Questionnaire Administration
Drug: Oxycodone Hydrochloride

First Posted Date: 2015-08-25

Last Posted Date: 2022-07-25

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 60

Registration Number: NCT02531906

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Acupuncture-Like Transcutaneous Electrical Nerve Stimulation in Treating Radiation-Induced Xerostomia in Patients With Head and Neck Cancer

Not Applicable

Completed

Conditions: Head and Neck Carcinoma
Xerostomia

Interventions: Other: Quality-of-Life Assessment
Procedure: Transcutaneous Acupoint Electrical Stimulation

First Posted Date: 2015-06-17

Last Posted Date: 2022-07-25

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 30

Registration Number: NCT02474095

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2

Active, not recruiting

Conditions: Glioblastoma
Gliosarcoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Montanide ISA 51 VG
Biological: Sargramostim
Biological: SVN53-67/M57-KLH Peptide Vaccine
Drug: Temozolomide

First Posted Date: 2015-05-28

Last Posted Date: 2024-03-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 66

Registration Number: NCT02455557

Locations: 🇺🇸
Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 2 locations

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

Phase 2

Terminated

Conditions: Lung Non-Squamous Non-Small Cell Carcinoma
Radiation-Induced Pneumonitis
Stage II Lung Non-Small Cell Cancer AJCC v7
Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
Stage IIB Lung Non-Small Cell Carcinoma AJCC v7
Stage III Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions: Other: Placebo
Biological: Durvalumab
Procedure: Quality-of-Life Assessment
Drug: Nintedanib

First Posted Date: 2015-05-22

Last Posted Date: 2020-04-06

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 8

Registration Number: NCT02452463

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

Phase 1

Recruiting

Conditions: Neoplasms, Ovarian
Ovary Neoplasms
Ovarian Cancer
Cancer of Ovary
Cancer of the Ovary
Ovary Cancer

Interventions: Biological: Cisplatin + celecoxib + DC vaccine
Biological: Cisplatin + CKM + Celecoxib + DC Vaccine

First Posted Date: 2015-05-04

Last Posted Date: 2024-08-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 25

Registration Number: NCT02432378

Locations: 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
UPMC CancerCenter at Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy